These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20523727)

  • 1. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
    Carlin S; Khan N; Ku T; Longo VA; Larson SM; Smith-Jones PM
    PLoS One; 2010 May; 5(5):e10857. PubMed ID: 20523727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
    Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
    Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
    Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
    Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
    Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
    van Brussel AS; Adams A; Vermeulen JF; Oliveira S; van der Wall E; Mali WP; van Diest PJ; van Bergen En Henegouwen PM
    Breast Cancer Res Treat; 2013 Jul; 140(2):263-72. PubMed ID: 23860929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
    Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
    Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
    Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
    Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.
    Askoxylakis V; Ehemann V; Rana S; Krämer S; Rahbari NN; Debus J; Haberkorn U
    Int J Mol Sci; 2012 Oct; 13(10):13030-48. PubMed ID: 23202936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.
    McIntyre A; Patiar S; Wigfield S; Li JL; Ledaki I; Turley H; Leek R; Snell C; Gatter K; Sly WS; Vaughan-Jones RD; Swietach P; Harris AL
    Clin Cancer Res; 2012 Jun; 18(11):3100-11. PubMed ID: 22498007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical validation of
    Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
    Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.
    Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S
    Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
    Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
    Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy.
    van Kuijk SJ; Gieling RG; Niemans R; Lieuwes NG; Biemans R; Telfer BA; Haenen GR; Yaromina A; Lambin P; Dubois LJ; Williams KJ
    PLoS One; 2016; 11(8):e0161040. PubMed ID: 27513947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
    Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
    Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells.
    van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S
    Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.